← Back to Clinical Trials
Recruiting NCT04127552

NCT04127552 Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04127552
Status Recruiting
Phase
Sponsor University of Roma La Sapienza
Condition Adrenal Incidentaloma
Study Type OBSERVATIONAL
Enrollment 68 participants
Start Date 2019-01-02
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Adrenalectomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 68 participants in total. It began in 2019-01-02 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators hypothesize that cardiovascular and metabolic alterations can occur in patients with adrenal adenomas and possible Autonomous Cortisol Secretion (pACS). Investigators hypothesize that adrenalectomy in selected patients, following the 2016 European Congress of Endocrinology (ECE) guidelines, can improve metabolic parameters and cardiovascular risks and features.

Eligibility Criteria

Inclusion Criteria: * Incidentally detected adrenal mass Exclusion Criteria: * Patients with overt Cushing's syndrome, pheochromocytoma, Conn syndrome, adrenocortical carcinoma, late-onset congenital adrenal hyperplasia, adrenal metastasis and adrenal hemorrhage * Patients taking medications influencing glucocorticoid production or metabolism * Patients with psychiatric diseases or alcohol abuse * Pregnancy

Contact & Investigator

Principal Investigator

Andrea M Isidori, MD, PHD

PRINCIPAL INVESTIGATOR

Sapienza

Frequently Asked Questions

Who can join the NCT04127552 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Adrenal Incidentaloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04127552 currently recruiting?

Yes, NCT04127552 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Roma La Sapienza to inquire about joining.

Where is the NCT04127552 trial being conducted?

This trial is being conducted at Rome, Italy.

Who is sponsoring the NCT04127552 clinical trial?

NCT04127552 is sponsored by University of Roma La Sapienza. The principal investigator is Andrea M Isidori, MD, PHD at Sapienza. The trial plans to enroll 68 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology